Skip to content

GeneDx Holdings WGS Other intangible assets—net

Other intangible assets—net at other companies

Natera, Inc. logo
Natera, Inc.NTRA
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Quest Diagnostics logo
Quest DiagnosticsDGX
Revvity logo
RevvityRVTY
Labcorp Holdings logo
Labcorp HoldingsLH

Other financials

Income statement

See full
Revenue$102.3M+17.4%
Gross profit$68.2M+16.6%
Operating income-$57.5M-1,163%
Net income-$63.3M-870%
EPS (diluted)-$2.16-839%

Balance sheet

See full
Cash & equivalents$94.9M-5.7%
Total debt$96.7M+82.5%
Total equity$254.1M-1.3%
Total assets$506.3M+13.4%

Cash flow

See full
Operating cash flow-$32.4M-418%
CapEx$6.5M+5.3%
Free cash flow-$38.9M-1,059%

Valuation

See full
Market cap$1.72B-24.3%
Enterprise value$1.73B-22.8%
P/S3.9×-3.0×

Profitability

See full
Gross margin69.6%+4.3pp
Operating margin-14.9%
Net margin-17.6%
FCF margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-30.4%
Debt / equity0.4×+0.2×
Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's other intangible assets—net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GeneDx Holdings's other intangible assets—net?
GeneDx Holdings (WGS) reported other intangible assets—net of $144.97M in Q1 2026.
How has GeneDx Holdings's other intangible assets—net changed year-over-year?
GeneDx Holdings's other intangible assets—net decreased by 6.5% year-over-year, from $155.09M to $144.97M.
What does other intangible assets—net mean?
This represents the net book value of identifiable non-physical assets such as patents, intellectual property, software licenses, and trademarks, excluding goodwill. These assets are vital for companies relying on proprietary technology and R&D. It captures the value of the company's competitive moat derived from its intellectual property portfolio.